$MED
MEDIFAST INC

2021 Q4 Form 10-K Financial Statement

#000162828022003534 Filed on February 23, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $377.8M $1.526B $264.9M
YoY Change 42.63% 63.25% 55.25%
Cost Of Revenue $99.55M $398.5M $65.70M
YoY Change 51.52% 68.12% 54.23%
Gross Profit $278.3M $1.128B $199.2M
YoY Change 39.67% 61.59% 55.57%
Gross Profit Margin 73.65% 73.89% 75.21%
Selling, General & Admin $230.3M $911.4M $160.4M
YoY Change 43.61% 61.69% 47.83%
% of Gross Profit 82.77% 80.82% 80.51%
Research & Development $1.100M $4.400M $900.0K
YoY Change 22.22% 57.14% 0.0%
% of Gross Profit 0.4% 0.39% 0.45%
Depreciation & Amortization -$463.0K $6.812M $2.000M
YoY Change -123.15% 57.83% 66.67%
% of Gross Profit -0.17% 0.6% 1.0%
Operating Expenses $231.4M $915.8M $161.2M
YoY Change 43.58% 61.66% 47.48%
Operating Profit $46.84M $216.2M $38.04M
YoY Change 23.13% 61.18% 102.68%
Interest Expense -$93.00K -$231.0K $0.00
YoY Change -193.9% -100.0%
% of Operating Profit -0.2% -0.11% 0.0%
Other Income/Expense, Net $7.000K -$112.0K -$200.0K
YoY Change -103.5% -205.66%
Pretax Income $46.75M $216.1M $37.85M
YoY Change 23.52% 60.97% 99.41%
Income Tax $12.73M $52.10M $9.900M
% Of Pretax Income 27.23% 24.11% 26.16%
Net Earnings $34.02M $164.0M $27.99M
YoY Change 21.54% 59.47% 40.81%
Net Earnings / Revenue 9.0% 10.75% 10.57%
Basic Earnings Per Share $14.01 $2.38
Diluted Earnings Per Share $2.900M $13.89 $2.36
COMMON SHARES
Basic Shares Outstanding 11.62M 11.71M shares 11.77M
Diluted Shares Outstanding 11.81M shares

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $213.7M $109.5M $338.2M
YoY Change -36.8% -37.22% 99.35%
Cash & Equivalents $104.2M $104.2M $163.7M
Short-Term Investments $109.5M $5.361M $174.5M
Other Short-Term Assets $16.33M $16.33M $5.900M
YoY Change 176.85% 176.85% -3.28%
Inventory $180.0M $180.0M $53.39M
Prepaid Expenses
Receivables $584.0K
Other Receivables $0.00
Total Short-Term Assets $306.9M $306.9M $234.3M
YoY Change 30.96% 30.97% 52.0%
LONG-TERM ASSETS
Property, Plant & Equipment $56.13M $80.59M $27.63M
YoY Change 103.13% 111.52% 6.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.468M $10.87M $2.937M
YoY Change 120.22% 202.0% 732.01%
Total Long-Term Assets $91.46M $91.46M $41.77M
YoY Change 118.96% 118.8% 3.13%
TOTAL ASSETS
Total Short-Term Assets $306.9M $306.9M $234.3M
Total Long-Term Assets $91.46M $91.46M $41.77M
Total Assets $398.3M $398.3M $276.1M
YoY Change 44.28% 44.27% 41.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $163.3M $70.89M $107.7M
YoY Change 51.63% 98.03% 41.34%
Accrued Expenses $6.523M $73.70M $3.700M
YoY Change 76.3% 36.23% 15.63%
Deferred Revenue $8.050M $7.606M
YoY Change 5.84% 75.54%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $169.8M $169.8M $111.4M
YoY Change 52.52% 52.45% 40.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $26.02M $26.02M $7.500M
YoY Change 246.93% 246.93% -27.88%
Total Long-Term Liabilities $26.02M $26.02M $7.500M
YoY Change 246.93% 246.93% -27.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $169.8M $169.8M $111.4M
Total Long-Term Liabilities $26.02M $26.02M $7.500M
Total Liabilities $195.9M $195.9M $118.8M
YoY Change 64.81% 64.86% 32.31%
SHAREHOLDERS EQUITY
Retained Earnings $190.3M $154.4M
YoY Change 23.31% -8.55%
Common Stock $12.00K $12.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $202.5M $202.5M $157.2M
YoY Change
Total Liabilities & Shareholders Equity $398.3M $398.3M $276.1M
YoY Change 44.28% 44.27% 41.83%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income $34.02M $164.0M $27.99M
YoY Change 21.54% 59.47% 40.81%
Depreciation, Depletion And Amortization -$463.0K $6.812M $2.000M
YoY Change -123.15% 57.83% 66.67%
Cash From Operating Activities -$7.459M $94.55M $19.80M
YoY Change -137.67% -34.88% 3.12%
INVESTING ACTIVITIES
Capital Expenditures -$11.62M $34.21M -$2.000M
YoY Change 481.2% 481.09% 122.22%
Acquisitions
YoY Change
Other Investing Activities $0.00 $5.145M $2.600M
YoY Change -100.0% 11.85%
Cash From Investing Activities -$11.62M -$29.06M $600.0K
YoY Change -2037.33% 2167.08% -175.0%
FINANCING ACTIVITIES
Cash Dividend Paid $63.86M
YoY Change 20.05%
Common Stock Issuance & Retirement, Net $56.00M
YoY Change 1019.98%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -31.23M -$125.1M -13.10M
YoY Change 138.41% 118.98% -41.78%
NET CHANGE
Cash From Operating Activities -7.459M $94.55M 19.80M
Cash From Investing Activities -11.62M -$29.06M 600.0K
Cash From Financing Activities -31.23M -$125.1M -13.10M
Net Change In Cash -50.31M -$59.54M 7.300M
YoY Change -789.25% -168.63% -278.05%
FREE CASH FLOW
Cash From Operating Activities -$7.459M $94.55M $19.80M
Capital Expenditures -$11.62M $34.21M -$2.000M
Free Cash Flow $4.165M $60.34M $21.80M
YoY Change -80.89% -56.69% 8.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
4980000 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.023
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.009
CY2021Q4 us-gaap Deferred Tax Liabilities Deferred Expense
DeferredTaxLiabilitiesDeferredExpense
7575000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Deferred Expense
DeferredTaxLiabilitiesDeferredExpense
4680000 USD
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0000910329
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity File Number
EntityFileNumber
001-31573
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity Registrant Name
EntityRegistrantName
Medifast, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3714405
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
100 International Drive
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
21202
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Baltimore
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2021 dei City Area Code
CityAreaCode
410
CY2021 dei Local Phone Number
LocalPhoneNumber
581-8042
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
MED
CY2021 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
false
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
3300000000 USD
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11542630 shares
CY2021 dei Auditor Firm
AuditorFirmId
49
CY2021 dei Auditor Name
AuditorName
RSM US LLP
CY2021 dei Auditor Location
AuditorLocation
Baltimore, Maryland
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1526087000 USD
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
934842000 USD
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
713672000 USD
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
398490000 USD
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
237027000 USD
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
176814000 USD
CY2021 us-gaap Gross Profit
GrossProfit
1127597000 USD
CY2020 us-gaap Gross Profit
GrossProfit
697815000 USD
CY2019 us-gaap Gross Profit
GrossProfit
536858000 USD
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
911356000 USD
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
563656000 USD
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
445819000 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
216241000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
134159000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
91039000 USD
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-231000 USD
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
246000 USD
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1295000 USD
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
119000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-140000 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29000 USD
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-112000 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
106000 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1324000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
216129000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
134265000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
92363000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52098000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31406000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14447000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
164031000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
102859000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
77916000 USD
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
14.01
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.74
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.62
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11771000 shares
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
13.89
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.68
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.43
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11705000 shares
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11771000 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11813000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11850000 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12117000 shares
CY2021 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
5.68
CY2020 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
4.52
CY2019 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
3.38
CY2021 us-gaap Net Income Loss
NetIncomeLoss
164031000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
102859000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
77916000 USD
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
112000 USD
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-21000 USD
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000 USD
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-42000 USD
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
37000 USD
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
197000 USD
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
70000 USD
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
16000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
198000 USD
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
164101000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
102875000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
78114000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104183000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163723000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
180043000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
53392000 USD
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
5361000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
10752000 USD
CY2021Q4 us-gaap Prepaid Taxes
PrepaidTaxes
945000 USD
CY2020Q4 us-gaap Prepaid Taxes
PrepaidTaxes
0 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16334000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6447000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
306866000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
234314000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56131000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27633000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24457000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10508000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6468000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2937000 USD
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4404000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
692000 USD
CY2021Q4 us-gaap Assets
Assets
398326000 USD
CY2020Q4 us-gaap Assets
Assets
276084000 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
163309000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
107677000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6523000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3673000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
169832000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
111350000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26020000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7488000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
195852000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
118838000 USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11594000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11822000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11593000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11772000 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
12000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
12000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
12018000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7842000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
111000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
41000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
190333000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
154351000 USD
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0 shares
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
46 shares
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
0 USD
CY2020Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5000000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
202474000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
157246000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
398326000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
276084000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
164031000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
102859000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
77916000 USD
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6812000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4316000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4624000 USD
CY2021 med Operating Lease Expense Non Cash
OperatingLeaseExpenseNonCash
5069000 USD
CY2020 med Operating Lease Expense Non Cash
OperatingLeaseExpenseNonCash
3189000 USD
CY2019 med Operating Lease Expense Non Cash
OperatingLeaseExpenseNonCash
2624000 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
9903000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
6796000 USD
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4621000 USD
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9883000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
4520000 USD
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000 USD
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-212000 USD
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-17000 USD
CY2021 us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
89000 USD
CY2020 us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
320000 USD
CY2019 us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
454000 USD
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3715000 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
601000 USD
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1598000 USD
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
126651000 USD
CY2021 us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
945000 USD
CY2020 us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
-5169000 USD
CY2019 us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
5169000 USD
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9887000 USD
CY2020 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
4605000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1086000 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1936000 USD
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4543000 USD
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2741000 USD
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2615000 USD
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
54380000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
28010000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12111000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
94545000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
145196000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
84261000 USD
CY2021 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
5145000 USD
CY2019 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
3730000 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34209000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5887000 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10058000 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29064000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1282000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6328000 USD
CY2021 med Proceeds From Stock Options Exercised Executives And Directors
ProceedsFromStockOptionsExercisedExecutivesAndDirectors
811000 USD
CY2020 med Proceeds From Stock Options Exercised Executives And Directors
ProceedsFromStockOptionsExercisedExecutivesAndDirectors
1597000 USD
CY2019 med Proceeds From Stock Options Exercised Executives And Directors
ProceedsFromStockOptionsExercisedExecutivesAndDirectors
278000 USD
CY2021 us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
6089000 USD
CY2020 us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
551000 USD
CY2019 us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
14092000 USD
CY2021 us-gaap Payments Of Dividends
PaymentsOfDividends
63856000 USD
CY2020 us-gaap Payments Of Dividends
PaymentsOfDividends
53190000 USD
CY2019 us-gaap Payments Of Dividends
PaymentsOfDividends
35396000 USD
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
55999000 USD
CY2020 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
5000000 USD
CY2019 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
33114000 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-125133000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-57144000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-82324000 USD
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112000 USD
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-21000 USD
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1000 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-59540000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
86749000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4390000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163723000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76974000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81364000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104183000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163723000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76974000 USD
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
56758000 USD
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
24636000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
109106000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
77916000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
4520000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
104832000 USD
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
17314000 USD
CY2021 us-gaap Dividends Cash
DividendsCash
17186000 USD
CY2020 us-gaap Dividends Cash
DividendsCash
13831000 USD
CY2019 us-gaap Dividends Cash
DividendsCash
13719000 USD
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
278000 USD
CY2019 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
14092000 USD
CY2019 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
33114000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
198000 USD
CY2019 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
39980000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
102859000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
6796000 USD
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1597000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
202474000 USD
CY2020 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
551000 USD
CY2020 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
5000000 USD
CY2020 us-gaap Treasury Stock Shares Retired
TreasuryStockSharesRetired
489000 shares
CY2020 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
0 USD
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
16000 USD
CY2020 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
53303000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
157246000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
164031000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
9596000 USD
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
811000 USD
CY2021 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6089000 USD
CY2021 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
55999000 USD
CY2021 us-gaap Treasury Stock Shares Retired
TreasuryStockSharesRetired
284000 shares
CY2021 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
0 USD
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
70000 USD
CY2021 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
67192000 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span>
CY2021 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Certain amounts reported for prior periods have been reclassified to be consistent with the current period presentation. No reclassification in the consolidated financial statements had a material impact on the presentation.</span>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our cash and cash equivalents and available-for-sale securities are maintained at several financial institutions and the balances with these financial institutions often exceed the amount of insurance provided on such accounts by the Federal Deposit Insurance Corporation. The cash and cash equivalents generally are maintained with financial institutions with reputable credit, and therefore bear minimal credit risk. Historically, we have not experienced any losses due to such concentration of credit risk.</span>
CY2021 us-gaap Advertising Expense
AdvertisingExpense
1600000 USD
CY2020 us-gaap Advertising Expense
AdvertisingExpense
4400000 USD
CY2019 us-gaap Advertising Expense
AdvertisingExpense
5300000 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4400000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2800000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2700000 USD
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
15196000 USD
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
13428000 USD
CY2021Q4 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
3641000 USD
CY2020Q4 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
4071000 USD
CY2021Q4 med Inventory Non Food Finished Goods
InventoryNonFoodFinishedGoods
15991000 USD
CY2020Q4 med Inventory Non Food Finished Goods
InventoryNonFoodFinishedGoods
8078000 USD
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
152687000 USD
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
29858000 USD
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7472000 USD
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2043000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
180043000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
53392000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
88830000 USD
CY2021 med Effective Income Tax Rate Reconciliation Nondeductible Expense Other Amount Executive Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherAmountExecutiveCompensation
2652000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
54725000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32699000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27092000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56131000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27633000 USD
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
70894000 USD
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
36092000 USD
CY2021Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
28733000 USD
CY2020Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
22598000 USD
CY2021Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
17186000 USD
CY2020Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
13831000 USD
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
24940000 USD
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
16948000 USD
CY2021Q4 med Promotional Sales Incentive Accruals
PromotionalSalesIncentiveAccruals
10935000 USD
CY2020Q4 med Promotional Sales Incentive Accruals
PromotionalSalesIncentiveAccruals
7621000 USD
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8050000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7606000 USD
CY2021Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
2571000 USD
CY2020Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
2981000 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
163309000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
107677000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
164031000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
102859000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
77916000 USD
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11705000 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11771000 shares
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11771000 shares
CY2021 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
108000 shares
CY2020 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
79000 shares
CY2019 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
346000 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11813000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11850000 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12117000 shares
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
14.01
CY2021 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
238000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.74
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.62
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
13.89
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.68
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.43
CY2021Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
21500000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11594000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
600000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1600000 shares
CY2019Q3 med Stock Repurchase Program Additional Shares Authorized
StockRepurchaseProgramAdditionalSharesAuthorized
2000000 shares
CY2020 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
46000 shares
CY2021Q4 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
2084000 shares
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
800000 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1600000 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
300000 USD
CY2021 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
22000 shares
CY2020 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
6000 shares
CY2019 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
128000 shares
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163723000 USD
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9903000 USD
CY2020 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
156000 shares
CY2021 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
116000 shares
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6796000 USD
CY2019 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
161000 shares
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4520000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
90000 USD
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
12849000 USD
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-3424000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-22000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
21000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
63000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
111000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
41000 USD
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
109464000 USD
CY2021 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
21000 USD
CY2021Q4 us-gaap Interest Receivable
InterestReceivable
59000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
109544000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104183000 USD
CY2021Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
5361000 USD
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
174241000 USD
CY2020 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
87000 USD
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
147000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
174475000 USD
CY2020Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
10752000 USD
CY2019 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
0 USD
CY2020 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
0 USD
CY2021 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
0 USD
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 USD
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
49433000 USD
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
28520000 USD
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
11024000 USD
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
6380000 USD
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2285000 USD
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1825000 USD
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
55813000 USD
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
30805000 USD
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-729000 USD
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
477000 USD
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
2323000 USD
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-291000 USD
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-77000 USD
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
201000 USD
CY2019 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
4000 USD
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3715000 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
601000 USD
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1598000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52098000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31406000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14447000 USD
CY2021 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
52200000 USD
CY2020 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
31400000 USD
CY2019 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
14500000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31406000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14447000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52098000 USD
CY2021 med Unrealized Gain Loss On Investment Securities And Foreign Currency Income Tax Effects Allocated To Equity
UnrealizedGainLossOnInvestmentSecuritiesAndForeignCurrencyIncomeTaxEffectsAllocatedToEquity
66000 USD
CY2020 med Unrealized Gain Loss On Investment Securities And Foreign Currency Income Tax Effects Allocated To Equity
UnrealizedGainLossOnInvestmentSecuritiesAndForeignCurrencyIncomeTaxEffectsAllocatedToEquity
14000 USD
CY2019 med Unrealized Gain Loss On Investment Securities And Foreign Currency Income Tax Effects Allocated To Equity
UnrealizedGainLossOnInvestmentSecuritiesAndForeignCurrencyIncomeTaxEffectsAllocatedToEquity
75000 USD
CY2021 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
52164000 USD
CY2020 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
31420000 USD
CY2019 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
14522000 USD
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
45405000 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
28196000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
19396000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.009
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.002
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
370000 USD
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-1835000 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.008
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-415000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.003
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1470000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.011
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
864000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.003
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-6424000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.070
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
503000 USD
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
579000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.006
CY2021 med Effective Income Tax Rate Reconciliation Nondeductible Expense Other Executive Compensation Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherExecutiveCompensationPercent
0.012
CY2020 med Effective Income Tax Rate Reconciliation Nondeductible Expense Other Amount Executive Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherAmountExecutiveCompensation
966000 USD
CY2020 med Effective Income Tax Rate Reconciliation Nondeductible Expense Other Executive Compensation Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherExecutiveCompensationPercent
0.007
CY2019 med Effective Income Tax Rate Reconciliation Nondeductible Expense Other Amount Executive Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherAmountExecutiveCompensation
442000 USD
CY2019 med Effective Income Tax Rate Reconciliation Nondeductible Expense Other Executive Compensation Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherExecutiveCompensationPercent
0.004
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
468000 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.002
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1342000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.010
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
0 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
808000 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.004
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
16000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
744000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.234
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14447000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.156
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52098000 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.241
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31406000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2022000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
753000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3052000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2546000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
420000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1015000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7130000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
4240000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
3274000 USD
CY2021Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
3514000 USD
CY2020Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
120000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
7191000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
2178000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1904000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1436000 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
18535000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8450000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
5375000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
2032000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
6000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
24000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
1175000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
1022000 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.021
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6207000 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
14131000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7758000 USD
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
4404000 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
692000 USD
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
28400000 USD
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
5600000 USD
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
3600000 USD
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
3100000 USD
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
4504000 USD
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
3775000 USD
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
18872000 USD
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
887000 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y4M24D
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5693000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5825000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
4160000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
5412000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
34427000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1884000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
32543000 USD

Files In Submission

Name View Source Status
0001628280-22-003534-index-headers.html Edgar Link pending
0001628280-22-003534-index.html Edgar Link pending
0001628280-22-003534.txt Edgar Link pending
0001628280-22-003534-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
med-20211231.htm Edgar Link pending
med-20211231.xsd Edgar Link pending
med-20211231x10kxex211.htm Edgar Link pending
med-20211231x10kxex231.htm Edgar Link pending
med-20211231x10kxex311.htm Edgar Link pending
med-20211231x10kxex312.htm Edgar Link pending
med-20211231x10kxex32.htm Edgar Link pending
med-20211231_cal.xml Edgar Link unprocessable
med-20211231_def.xml Edgar Link unprocessable
med-20211231_g1.jpg Edgar Link pending
med-20211231_htm.xml Edgar Link completed
med-20211231_lab.xml Edgar Link unprocessable
med-20211231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending